2021-08-10FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinomaTrial CLEARDrugs Lenvima (lenvatinib) · Multikinase inhibitor, Keytruda (pembrolizumab) · Anti-PD-1 antibodyConditionGenitourinary
2021-07-21FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinomaTrial MK-3475-775Drugs Keytruda (pembrolizumab) · Anti-PD-1 antibody, Lenvima (lenvatinib) · Multikinase inhibitorConditionGynecologic
2019-09-17Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and USDrugs KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, LENVIMA (lenvatinib) · Multikinase inhibitor
2019-08-02FDA approves pexidartinib for tenosynovial giant cell tumorTrial ENLIVENDrug TURALIO (pexidartinib) · Multikinase inhibitorConditionSarcoma
2018-08-16FDA approves lenvatinib for unresectable hepatocellular carcinomaDrug Lenvima (lenvatinib) · Multikinase inhibitorConditionGastrointestinal
2016-05-13Lenvatinib in combination with EverolimusDrugs Lenvima (lenvatinib) · Multikinase inhibitor, everolimus · MTOR inhibitor